Ray Dalio's BBIO Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 43,172 shares of BridgeBio Pharma, Inc. (BBIO) worth $3.3 M, representing 0.01% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 1 quarters.
Based on recent 13F filings, Ray Dalio has initiated a new position in BBIO, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's BridgeBio Pharma (BBIO) Holding Value Over Time
Track share changes against reported price movement
Quarterly BridgeBio Pharma (BBIO) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +43,172 | New Buy | 43,172 | $76.49 |
Ray Dalio's BridgeBio Pharma Investment FAQs
Ray Dalio first purchased BridgeBio Pharma, Inc. (BBIO) in Q4 2025, acquiring 43,172 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held BridgeBio Pharma, Inc. (BBIO) for 1 quarters since Q4 2025.
Ray Dalio's largest addition to BridgeBio Pharma, Inc. (BBIO) was in Q4 2025, adding 43,172 shares worth $3.3 M.
According to the latest 13F filing for Q4 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 43,172 shares of BridgeBio Pharma, Inc. (BBIO), valued at approximately $3.3 M.
As of the Q4 2025 filing, BridgeBio Pharma, Inc. (BBIO) represents approximately 0.01% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in BridgeBio Pharma, Inc. (BBIO) was 43,172 shares, as reported at the end of Q4 2025.